<DOC>
	<DOCNO>NCT02951637</DOCNO>
	<brief_summary>The purpose study compare chemotherapy gefitinib combination gefitinib alone first-line therapy adenocarcinoma , term efficacy safety .</brief_summary>
	<brief_title>Chemotherapy Plus Gefitinib Advanced Lung Adenocarcinoma Sensitive EGFR Mutations : Randomized Controlled Trial</brief_title>
	<detailed_description>The primary endpoint compare progression-free survival ( PFS ) pemetrexed plus carboplatin combine gefitinib gefitinib alone first-line therapy lung adenocarcinoma . In addition , overall survival safety index collect analysis .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients voluntarily join study give write informed consent study ; 2 . Histologically document , unresectable , inoperable , locally advanced , recurrent metastatic stage IIIB IV NonSmall Cell Lung Cancer ( NSCLC ) ; 3 . A cytologic diagnosis acceptable ( FNA pleural fluid cytology ) 4 . Sensitive EGFR mutation ( 19del , 21L858R ) ; 5 . At least 1 unidimensionally measurable lesion meeting Response Evaluation Criteria Solid Tumours ( RECIST ) criteria ; 6 . Patients receive systemic anticancer therapy previously ; 7 . Able comply study followup procedure ; 8 . Age &gt; = 18 year , ECOG PS : 01 , estimate survival duration 3 month ; 1 . Small cell lung cancer ( include patient mixed small cell lung cancer nonsmall cell lung cancer ) ; 2 . Evidence small cell , carcinoid , mixed small cell/nonsmall cell histology ; 3 . EGFR wildtype patient , patient rare EGFR mutation complex EGFR mutation ; 4 . Previously ( within 5 year ) presently suffer malignancy , except cured cervical carcinoma situ , nonmelanoma skin cancer superficial bladder cancer [ Ta ( noninvasive carcinoma ) , Tis ( carcinoma situ ) T1 ( invasion lamina propria ) ] ; 5 . Symptomatic untreated brain metastasis ; 6 . Unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , serious cardiac arrhythmia require medication ( patient chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia , eligible ) ; 7 . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication ; 8 . Gastrointestinal tract disease result inability take oral medication requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption ; 9 . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adenocarcinoma , EGFR , Gefitinib , Pemetrexed , Carboplatin</keyword>
</DOC>